ethidium has been researched along with Multiple Sclerosis in 12 studies
Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.
ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study reveals that long-term administration of GST for 28 days has a neuroprotective effect by improving behavioral deficits (spatial cognition memory, grip, and motor coordination) associated with lower STAT-3 levels." | 5.62 | Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain. ( Gupta, R; Khera, R; Kumar, N; Mehan, S; Sharma, N, 2021) |
| " The present study reveals that long-term administration of GST for 28 days has a neuroprotective effect by improving behavioral deficits (spatial cognition memory, grip, and motor coordination) associated with lower STAT-3 levels." | 1.62 | Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain. ( Gupta, R; Khera, R; Kumar, N; Mehan, S; Sharma, N, 2021) |
| "Multiple sclerosis is a demyelinating disease of the central nervous system associated with varied levels of disability." | 1.35 | Effects of aquatic exercises in a rat model of brainstem demyelination with ethidium bromide on the beam walking test. ( Alouche, SR; Bondan, EF; Nassar, CC, 2009) |
| "We conclude that stathmin expression in demyelinating disorders could have a dual role." | 1.33 | Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders. ( Bruck, W; Casaccia-Bonnefil, P; Liu, A; Mastronardi, FG; Moscarello, M; Sobel, A; Stadelmann, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Upadhayay, S | 1 |
| Mehan, S | 3 |
| Prajapati, A | 1 |
| Sethi, P | 1 |
| Suri, M | 2 |
| Zawawi, A | 1 |
| Almashjary, MN | 1 |
| Tabrez, S | 1 |
| Kapoor, T | 1 |
| Sharma, N | 2 |
| Kumar, N | 2 |
| Narula, AS | 1 |
| Alshammari, A | 1 |
| Alasmari, AF | 1 |
| Alharbi, M | 1 |
| Assiri, MA | 1 |
| Kalfin, R | 1 |
| Motavallihaghi, S | 1 |
| Ghaemipanaeian, M | 1 |
| Soleimani Asl, S | 1 |
| Foroughi-Parvar, F | 1 |
| Maghsood, AH | 1 |
| Khera, R | 1 |
| Gupta, R | 1 |
| Hooijmans, CR | 1 |
| Hlavica, M | 1 |
| Schuler, FAF | 1 |
| Good, N | 1 |
| Good, A | 1 |
| Baumgartner, L | 1 |
| Galeno, G | 1 |
| Schneider, MP | 1 |
| Jung, T | 1 |
| de Vries, R | 1 |
| Ineichen, BV | 1 |
| Nassar, CC | 1 |
| Bondan, EF | 1 |
| Alouche, SR | 1 |
| Zambonin, JL | 1 |
| Zhao, C | 2 |
| Ohno, N | 1 |
| Campbell, GR | 1 |
| Engeham, S | 1 |
| Ziabreva, I | 1 |
| Schwarz, N | 1 |
| Lee, SE | 1 |
| Frischer, JM | 1 |
| Turnbull, DM | 1 |
| Trapp, BD | 1 |
| Lassmann, H | 1 |
| Franklin, RJ | 3 |
| Mahad, DJ | 1 |
| Arnett, HA | 1 |
| Fancy, SP | 1 |
| Alberta, JA | 1 |
| Plant, SR | 1 |
| Kaing, S | 1 |
| Raine, CS | 1 |
| Rowitch, DH | 1 |
| Stiles, CD | 1 |
| Liu, A | 1 |
| Stadelmann, C | 1 |
| Moscarello, M | 1 |
| Bruck, W | 1 |
| Sobel, A | 1 |
| Mastronardi, FG | 1 |
| Casaccia-Bonnefil, P | 1 |
| Fernandes, CG | 1 |
| Graça, DL | 1 |
| Pereira, LA | 1 |
| Smith, PM | 1 |
| Blakemore, WF | 1 |
| Chari, DM | 1 |
| Gilson, JM | 1 |
| Crang, AJ | 1 |
1 review available for ethidium and Multiple Sclerosis
| Article | Year |
|---|---|
Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis.
Topics: Animals; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, E | 2019 |
11 other studies available for ethidium and Multiple Sclerosis
| Article | Year |
|---|---|
Nrf2/HO-1 Signaling Stimulation through Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) Provides Neuroprotection in Ethidium Bromide-Induced Experimental Model of Multiple Sclerosis.
Topics: Animals; Antioxidants; Ethidium; Heme Oxygenase-1; Models, Theoretical; Multiple Sclerosis; Neuropro | 2022 |
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis.
Topics: Adenylyl Cyclases; Animals; Colforsin; Cytokines; Demyelinating Diseases; Donepezil; Ethidium; Fingo | 2022 |
Toxoplasma gondii attenuates the ethidium bromide induced demyelination lesions in multiple sclerosis model rats.
Topics: Animals; Cytokines; Ethidium; Multiple Sclerosis; Neurodegenerative Diseases; Rats; Toxoplasma; Toxo | 2023 |
Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain.
Topics: Acetylcholinesterase; Animals; Brain; Disease Models, Animal; Dopamine; Ethidium; Female; Glutamic A | 2021 |
Effects of aquatic exercises in a rat model of brainstem demyelination with ethidium bromide on the beam walking test.
Topics: Animals; Disease Models, Animal; Ethidium; Male; Multiple Sclerosis; Physical Conditioning, Animal; | 2009 |
Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ax | 2011 |
bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS.
Topics: Animals; Animals, Newborn; Basic Helix-Loop-Helix Transcription Factors; Brain; Cell Nucleus; Cupriz | 2004 |
Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders.
Topics: Animals; Apoptosis; Brain; Cell Differentiation; Cells, Cultured; Demyelinating Diseases; Epilepsy, | 2005 |
Inflammatory response of the spinal cord to multiple episodes of blood-brain barrier disruption and toxic demyelination in Wistar rats.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Demyelinating Diseases; Ethidium; Female; Inje | 1998 |
The effect of immunosuppressive protocols on spontaneous CNS remyelination following toxin-induced demyelination.
Topics: Animals; Cyclophosphamide; Cyclosporine; Demyelinating Diseases; Drug Therapy, Combination; Enzyme I | 2001 |
Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS.
Topics: Animals; Animals, Newborn; Brain Tissue Transplantation; Cell Movement; Demyelinating Diseases; Enzy | 2002 |